On Wednesday 17th March the Duchenne Research Fund hosted a virtual evening to share updates with supporters about research funded by the charity. Our co-founders Kerry & Doron Rosenfeld welcomed more than 200 viewers from across five continents who came together...
We are pleased to share that we have awarded a grant of £35,000 to Great Ormond Street Hospital to establish a dedicated clinic for children who are non-ambulant (no longer able to walk). The grant supports the post of Senior Physiotherapist Nicola Burnett (pictured)...
We are delighted to announce that Duchenne Research Fund has awarded £40,000 to the newly launched DMD Care UK, partnering with the project’s founders Duchenne UK and Joining Jack. Together our three charities will invest £130,000 in the nationwide initiative...
We are pleased to announce that the Duchenne Research Fund has places available for the 2021 Virgin Money London Marathon, which is due to take place on Sunday 3rd October. Whether you’re a seasoned runner or a first-time marathoner, we welcome all supporters...
ReveraGen BioPharma has received a $3.3 million grant from the NIH – the US National Institutes of Health – for their ongoing work on the steroid alternative treatment Vamorolone for Duchenne muscular dystrophy. The NIH Commercialization Readiness Pilot...
Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaboration and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne. The collaboration brings together Solid’s expertise in muscle biology...
Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne muscular dystrophy. Including 6 months treatment in the preceding study,...
Solid Biosciences has issued an update on IGNITE DMD, the Phase I/II clinical study with its microdystrophin gene therapy, SGT-001. The most recent child dosed in the study has experienced a serious adverse event (SAE), and thankfully, he is now improving. He is being...
The Duchenne Research Fund is pleased to share that the KineDMD study has been extended into 2021/22. KineDMD is Dr Aldo Faisal’s ground-breaking artificial intelligence study at Imperial College London, in collaboration with Great Ormond Street Hospital, which...
Congratulations to the #TeamDRF cyclists who once again took on the Prudential RideLondon-Surrey, and raised more than £5,000 to help combat Duchenne. The annual ride is one of Europe’s biggest sporting events, with more than 25,000 cyclists setting off from the...